secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001628280-25-017844
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead CFO Ken Myszkowski to retire May 13; Daniel Apel named new CFO
------------------------------------------------------------------------

- Ken Myszkowski will retire as CFO effective May 13, 2025, after 16 years; no disagreement cited.
- Daniel Apel, former Global Head of FP&A at Walgreens Boots Alliance and Bayer US CFO, appointed CFO same date.
- Apel receives $575K base salary, 45% target bonus, 100K RSUs vesting over 4 years, and up to $200K relocation.
- Myszkowski will serve as adviser through Jan 31, 2026, at $200K annual salary with continued benefits and equity vesting.
- CEO cites transition to commercial stage with planned plozasiran launch pending regulatory review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828025017844/0001628280-25-017844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828025017844/arwr-20250411.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-017844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer